Clinical Trials Logo

Clinical Trial Summary

It is not known if the use of NuvaRing® alters these innate and inflammatory biomarkers of inflammation.

Hypothesis:

The hypothesis is that NuvaRing® will alter inflammatory biomarkers of inflammation, such as vaginal defensin and cytokine levels, resulting in an overall anti-inflammatory milieu in the vagina.

Specific aims of this study are to:

1. Determine biomarkers of inflammation, including defensins and cytokines, concentrations in women with normal vaginal flora (Nugent Score 0 - 3) before and after NuvaRing® use

2. Determine changes in the integrity of cervicovaginal epithelium and leukocytic concentration before and after treatment with NuvaRing®

3. Monitor for changes in the Nugent score before and after NuvaRing® use

4. Assess the antimicrobial activity of vaginal fluid before and after NuvaRing® use

5. Assess HIV infectivity ex vivo on biopsy specimens before and after NuvaRing® use

Methods This is a prospective, open-label, nonrandomized study. Participants will serve as their own controls. The Clinical Research Center of Eastern Virginia Medical School, Norfolk, Virginia, U.S.A. will be the only study site.


Clinical Trial Description

1. To complete specific aim #1, the investigators will use commercially available elisa kits to measure human defensins, inflammatory cytokines, and anti-inflammatory cytokines in vaginal fluid washings collected before and after use of NuvaRing.

2. To complete specific aim #2, the investigators will collect biopsies of the uterine cervix before and after NuvaRing use. Specimens will undergo histopathological measures for overall appearance, epithelial integrity, epithelial thickness, leukocyte infiltration, congestion, and edema. The investigators will quantitate the number of CD45+ and NFkB+ cells using immunohistology in the cervical epithelium. ;


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01448291
Study type Interventional
Source Eastern Virginia Medical School
Contact Julia Caul
Phone 7574465808
Status Recruiting
Phase Phase 4
Start date October 2011
Completion date March 2013

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02558179 - Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method N/A
Completed NCT02272231 - Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
Completed NCT02314429 - Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis Phase 1
Completed NCT02139839 - Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14 Phase 0
Recruiting NCT03500107 - Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial N/A
Completed NCT00153517 - Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy Phase 2
Completed NCT04989543 - Study of the Composition and Bacterial Diversity of the Vaginal Microbiota in Healthy Versus Pathological Conditions (Bacterial Vaginosis) Using a Targeted Metagenomic Approach (RNA 16s) N/A
Completed NCT02641717 - Validity of Patient-Collected Wet Mounts N/A
Terminated NCT03943823 - Postmenopausal Pessary Users: Estrogen Versus Trimosan Phase 4
Completed NCT03134924 - Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention "WASH-2" N/A
Completed NCT01293643 - A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Phase 3
Terminated NCT01153958 - Colposeptine for the Treatment of Bacterial Vaginosis Phase 4
Completed NCT00484653 - Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman N/A
Completed NCT05649735 - EFFICACY AND SAFETY OF OVA AND LAVAGE MEDICAL DEVICES IN THE TREATMENT OF NON-SPECIFIC VULVOVAGINITIS N/A
Completed NCT02860845 - Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Phase 4
Not yet recruiting NCT00491270 - Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Phase 3
Completed NCT01055106 - Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis Phase 2
Terminated NCT01322971 - Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population N/A
Completed NCT04171947 - Vaginal Ovule With Flavonoid Tea Extract for the Correction of Imbalance in the Vaginal Environment N/A
Completed NCT02392026 - Safety and Tolerability of Metronidazole Gel 1.3% Phase 4